Organogenesis Holdings (ORGO) sells advanced wound care products with roughly 95% revenue exposure to CMS-reimbursed skin substitutes. Four CMS policy changes effective January 1, 2026 — flat $127.14/sq cm pricing, WISeR prior authorization in six states, LCD withdrawal, and a discarded-product comment — collapsed sector demand. The Q1 2026 10-Q filed May 7 contains three forensic items the consensus likely hasn't synthesized.

What the filing says

Advanced Wound Care revenue printed -63% YoY ($79.9M → $29.5M); total revenue -58%. Management's own guide on the Q4 2025 call was -50%. They missed by 13 percentage points on the first print after the policy reset. Gross margin collapsed 72.6% → 28.9%. Adjusted EBITDA -$48.2M (vs -$12.5M PY).

Q1 cash held nearly flat at $91.4M, which looks reassuring. It isn't. Accounts receivable collapsed from $217.5M to $116.9M — a $100M collection of the Q4 2025 channel pre-buy ahead of the cliff. Strip the AR delta from operating cash flow and underlying Q1 burn was approximately $80-100M. Q2 has no comparable unwind: the receivables base has normalized, and the MD&A now states the company is "continuing to experience a significant year-over-year decline in revenue in the second quarter of fiscal year 2026."

The $75M JPMorgan revolver expires August 6, 2026, and the filing does not disclose a renewal or extension. The Consolidated Interest Coverage Ratio covenant requires EBITDA to be at least 300% of cash interest expense over trailing four quarters; with Q1 adjusted EBITDA at -$48M, the test cannot be met. The revolver is effectively un-drawable without a covenant waiver. The going-concern statement explicitly relies on it through Aug 6.

What the market thinks

Stock down 51% YoY, sitting at 7% of its 52-week range. ATM implied volatility at the 322nd percentile versus trailing 52 weeks. Short float 28.8%, 6.8 days to cover. One sell-side firm (BTIG) actively covers, target $8 (+216% upside). Insider activity is minor — two directors purchased ≈$40K combined in March 2026.

The market sees the distress.

Why the gap exists

Three specific reasons. First, sell-side balance sheet models routinely treat undrawn revolver capacity as available liquidity without auditing the covenant tests in the credit agreement. Second, reported OCF gets quoted as a cash flow proxy without adjusting for working capital deltas — Q1 OCF +$21M absent the $100M AR collection was deeply negative. Third, the cohort calibration signal is still surfacing: ORGO missed its own guide; MDXG cut FY2026 revenue guidance by $80M midpoint after one quarter; TELA refused to provide 2026 guidance entirely. Convatec's May 21 trading update is the next test.

Risks, ranked

1. Covenant waiver + revolver extension (estimated 30-40% probability). Cheapest path for management. Defuses the Aug 6 catalyst.
2. Strategic alternatives or takeover speculation. 28.8% short float creates squeeze convexity on any positive announcement.
3. ReNu BLA acceptance. Rolling submission completed April 24, 2026 for knee osteoarthritis (outside CMS skin sub structure). Acceptance decision typically within 60 days. Long-dated optionality but doesn't help near-term liquidity.
4. Cash buffer absorbs true burn. $91M could plausibly cover 6-9 months of underlying losses even without the revolver.

Catalysts

What would change our mind

Bullish: revolver renewal or extension announced before mid-July; FDA priority-review designation on the ReNu BLA; insider open-market purchase exceeding $200K. Further bearish: going-concern qualification added by the auditor in the Q2 10-Q; convertible or equity raise priced below $2 per share; Q2 OCF below -$50M.

Evidence

LR signal: 0.75 (mild bearish — direction is priced; distribution shape, anchored on the un-drawable revolver and AR-unwind illusion, is not)